The Silent Epidemic: Kenya's Most Overlooked Canine Cancer
- Dr Andrew Matole, BVetMed, MSc
- 3 days ago
- 9 min read
Canine Transmissible Venereal Tumour (CTVT) in Dogs
A contagious cancer that spreads dog-to-dog—here’s what every pet owner in Kenya needs to know about recognition, treatment, and prevention.
What Is Canine Transmissible Venereal Tumour (CTVT/TVT)?
Canine transmissible venereal tumour (CTVT/TVT)—also called canine transmissible venereal sarcoma (CTVS), Sticker's tumour, or infectious sarcoma—is a naturally occurring, contagious neoplasm unique in oncology: it is one of only three known transmissible cancers in higher animals, the others being Tasmanian devil facial tumour disease and contagious reticulum cell sarcoma of hamsters (Ganguly et al., 2016). Unlike conventional cancers, TVT is caused not by a virus or bacterium but by the tumour cell itself acting as the infective agent—physically transplanted from one dog to another. TVT cells are classified as histiocytic round cell tumours. Their karyotype is distinctly aneuploid (approximately 57–64 chromosomes versus the normal canine karyotype of 78), and the same marker chromosomes appear in TVT samples worldwide, confirming that all cases descend from a single ancestral clone (Faro & de Oliveira, 2023).
A Truly Extraordinary Cancer: The tumour cell itself is the infectious particle. There is no oncogenic virus. The cancer has been continuously propagating as a living allograft for several thousand years, making it arguably the oldest known somatic cell lineage on earth (Strakova & Murchison, 2014).
Origin and Global Distribution
Clonal transfer of CTVT/TVT has been documented since the late 1800s, though molecular evidence suggests the founder cell arose in a wolf or early domestic dog several thousand years ago (Ganguly et al., 2016). Phylogenomic analysis indicates East Asian or Arctic canid origin (Faro & de Oliveira, 2023).
Today, CTVT/TVT is endemic in at least 90 countries across all inhabited continents (Strakova & Murchison, 2014). Prevalence exceeds 1% in at least 13 countries in South and Central America, 11 in Africa, and 8 in Asia. The disease is strongly associated with large populations of free-roaming, sexually intact dogs.
How CTVT Spreads
The primary route of transmission is coitus (sexual intercourse). During mating, trauma and abrasion of the genital mucosa facilitate implantation of shed tumour cells onto recipient tissue (Ganguly et al., 2016). However, TVT is emphatically not exclusively a venereal disease. Secondary routes include sniffing and licking (cells transferred to nasal, oral, or skin surfaces); dam-to-pup grooming (producing oral/nasal TVT in pups); biting during aggressive contact; and self-inoculation via scratching at tumours (Ganguly et al., 2016; Merck Veterinary Manual, 2024). A critical quorum of viable neoplastic cells must be transferred for successful engraftment—not every contact results in disease.
Which Dogs Are at Risk?
Dogs of any breed, age, or sex are biologically susceptible—no heritable breed predisposition has been confirmed (Ganguly et al., 2016). The highest-risk profile is free-roaming, sexually intact (unspayed/unneutered), sexually active dogs aged 2–5 years (Ganguly et al., 2016; Bouazza et al., 2024). Mixed-breed and stray dogs represent the majority of cases, reflecting unrestricted mating opportunities. Dogs in tropical and subtropical environments—including Kenya—face heightened exposure due to dense free-roaming dog populations.
Signs and Symptoms
Clinical presentation depends on tumour location. Lesions are characteristically cauliflower-like or pedunculated, friable, red, haemorrhagic masses that frequently ulcerate (Ganguly et al., 2016).
Key sites and associated signs:
Watch for these early warning signs: unexplained genital bleeding or discharge, frequent licking of the genitals, nosebleeds without trauma, and any unusual growths on or around the genitalia or muzzle should prompt immediate veterinary evaluation.
Diagnosis
A presumptive diagnosis is based on history, location, and gross appearance; a definitive diagnosis requires cytological and/or histopathological confirmation (Schectman et al., 2022).
Cytology (Fine Needle Aspiration)
Canine transmissible venereal tumour (CTVT) cytology is highly characteristic and typically sufficient for diagnosis. Smears reveal sheets of round cells with large nuclei, prominent nucleoli, and — the pathognomonic hallmark — numerous distinct, clear cytoplasmic vacuoles (Ganguly et al., 2016). These differentiate TVT from lymphoma, mast cell tumours, histiocytoma, and plasmacytoma. Three morphological variants are recognised: lymphocytic, plasmacytic, and tadpole—the latter two being associated with potential vincristine resistance (Bronhara Pimentel et al., 2025).
Histopathology
Reserved for atypical presentations. Microscopy shows packets of undifferentiated round cells partitioned by thin fibrovascular septa, with prominent nucleoli and numerous mitotic figures (Ganguly et al., 2016; Schectman et al., 2022). Dogs with confirmed TVT should receive baseline haematology, biochemistry, urinalysis, and thoracic/abdominal imaging to assess for metastatic spread — though true metastasis occurs in fewer than 5–17% of cases (Ganguly et al., 2016).
Is Canine Transmissible Venereal Tumour Transmissible to Humans?
No documented evidence exists showing that Canine Transmissible Venereal Tumour (CTVT/TVT) can infect, be transmitted to, or cause disease in humans. Academic research consistently classifies TVT as a strictly canine-specific disease with zero zoonotic potential (Ganguly et al., 2016; Kabir et al., 2019).
Why CTVT Cannot Infect Humans
Strict Species Barrier: CTVT is a clonal cell line that originated from an ancient canid ancestor thousands of years ago (Strakova & Murchison, 2014). It is adapted exclusively to dogs and closely related wild canids like foxes and coyotes, making it biologically incapable of thriving in non-canid hosts (Ganguly et al., 2016).
Immune System Rejection: The tumour spreads as an allograft, meaning the tumour cells themselves are the infectious agent, rather than a virus (Strakova & Murchison, 2014). While CTVT cells can downregulate their Major Histocompatibility Complex (MHC) to evade a dog's immune system, the human immune system immediately recognises these canine cells as foreign tissue and destroys them upon contact (Kabir et al., 2019).
Mechanisms of Transmission: Transmission requires the physical implantation of live, intact tumour cells onto damaged mucous membranes (Stull, 2024). It is not an airborne or waterborne pathogen, nor can it survive outside of a living host environment.
Safe Handling and Hygiene Protocols
While humans face no risk of contracting CTVT, veterinary staff and pet owners must still practise strict hygiene protocols when handling infected animals:
Wear examination gloves to prevent contact with the ulcerated, bleeding lesions, which frequently harbour secondary bacterial infections that can infect open wounds on human skin (Ganguly et al., 2016).
Wash hands thoroughly with antibacterial soap and water immediately after inspecting or treating an animal's oral, nasal, or genital lesions.
Isolate infected dogs from all other healthy, unsterilized canines, as the disease is highly contagious between dogs through routine social behaviors like mating, sniffing, and licking (Strakova & Murchison, 2014)
Treatment
TVT responds exceptionally well to treatment. Vincristine sulphate chemotherapy is the universally recognised gold standard, consistent across decades of clinical experience (Ganguly et al., 2016; Reis Filho, 2024).
First-line: Vincristine Sulphate Chemotherapy
Vincristine is administered as a slow intravenous injection at 0.5 mg/m² body surface area, given once weekly. Most uncomplicated cases achieve complete tumour regression after 3–6 weekly doses, with clinical improvement typically visible within 2–4 weeks (Ganguly et al., 2016; Reis Filho, 2024). An overall success rate exceeding 97% has been reported in large case series (Reis Filho, 2024).
Second-line and Adjunct Options
Doxorubicin: Employed in vincristine-resistant cases. Complete remission rates up to 90% (Reis Filho, 2024).
Radiation therapy: Highly effective, especially for nasal or orbital lesions (Ganguly et al., 2016).
Surgical excision: Not recommended as sole therapy — recurrence rate ~68% post-excision alone (Ganguly et al., 2016).
Emerging Option: Vincristine + Ivermectin Combination
Drug resistance to vincristine is a recognised concern in CTVT, and emerging evidence suggests it may be related to tumour cytomorphological patterns — specifically the plasmacytoid and lymphocytoid variants. A prospective clinical study (Bulhosa et al., 2020) evaluated whether adding ivermectin — a macrocyclic lactone with documented anticancer properties — to the standard vincristine protocol could improve outcomes.
In this randomised trial (n = 41 dogs characterised; n = 20 treated), dogs were allocated to either a vincristine-only group (G-Vin; n = 10) or a vincristine + ivermectin combination group (G-Iv/Vin; n = 10). Critically, dogs in the combination group presented with significantly more severe disease at enrolment (P = 0.0031), yet the number of weeks and chemotherapy sessions required to achieve tumour remission was similar between groups — indicating equivalent efficacy despite greater initial disease burden (Bulhosa et al., 2020). Importantly, the vincristine-only group showed significant neutropenia (P = 0.0371), whereas no neutropenia was recorded in the combination group. No tumour resistance developed in either group regardless of treatment regimen or cytomorphological pattern (Bulhosa et al., 2020).
NB: Do Not Delay Treatment: Spontaneous regression is unpredictable and cannot be relied upon. Untreated TVT can grow progressively, become resistant, ulcerate severely, and—rarely—metastasise to lymph nodes or the CNS.
Prognosis
With timely diagnosis and chemotherapy, prognosis is excellent. Most dogs achieve full and durable remission (Ganguly et al., 2016; Reis Filho, 2024). Prognosis becomes more guarded with widespread metastasis, encephalic involvement, or chemotherapy resistance. A successfully treated dog can contract TVT again upon re-exposure — there is no lasting protective immunity (Ganguly et al., 2016).
Prevention
Preventing CTVT rests on interrupting the opportunities for cell transmission:
Spay / Neuter: Eliminating mating behaviour drastically reduces CTVT transmission risk and provides broader health and population control benefits.
Controlled Access: Restrict contact between your dog and stray or free-roaming dogs. Unsupervised roaming in areas with stray dogs is a key risk factor.
Pre-breeding Exam: Always ensure breeding dogs undergo a thorough veterinary genital examination before mating to rule out active infection.
Routine Check-ups: Regular veterinary examinations allow early detection of subtle genital lesions before they become large or cause complications.
Community Action: Support responsible dog ownership, birth control programmes for stray dogs, and prompt veterinary care for affected animals.
Know the Signs: Early recognition is the most powerful tool. Any unexplained genital discharge or mass in your dog warrants immediate veterinary attention.
Transmissible Venereal Tumour (TVT) in Kenya
Kenya falls squarely within the CTVT-endemic zone (Strakova & Murchison, 2014). Clinical reports of CTVT in Kenyan dogs date to the early 1970s, with Rottcher (1972) among the earliest African case series in indexed veterinary literature. At The Andys Veterinary Clinic, we encounter TVT cases from both our Loresho (Nairobi) and Nanyuki branches, most commonly in intact dogs with outdoor access. Nairobi's peri-urban areas – where owned pets interact with semi-stray dogs – represent a significant exposure environment. We encourage all pet owners in suburbs with high stray dog densities to remain vigilant.
If you notice any warning signs described above, please contact The Andys Veterinary Clinic or your veterinarian. Do not hesitate. Early treatment is the difference between a simple course of chemotherapy and a prolonged management challenge.
References
Bouazza, A., Bouzekrini, M., Maatouk, M., Aniss, M., Harby, H., Belkasmi, F., Bencharif, D., Anajjar, B., El-Amiri, B., & Ouchaou, B. (2024). Canine transmissible venereal tumor in Morocco: Clinical and pathological findings in 64 dogs. Frontiers in Veterinary Science. https://doi.org/10.3389/fvets.2024.1395826
Bronhara Pimentel, P. A., Costa, M. P., Oliveira, A. R., Oliveira Paes, P. R., Pereira, A. W., & Horta, S. (2025). Chemoresistance cytological score for canine transmissible venereal tumour: A proposed system of predicting vincristine resistance. Veterinary and Comparative Oncology, 23(2), 278–289. https://doi.org/10.1111/vco.13054
Bulhosa, L. F., Estrela-Lima, A., Solcà, M. da S., Gonçalves, G. S. D., Larangeira, D. F., Pinho, F. A. de, & Barrouin-Melo, S. M. (2020). Vincristine and ivermectin combination chemotherapy in dogs with natural transmissible venereal tumor of different cyto-morphological patterns. Animal Reproduction Science, 216, 106358. https://doi.org/10.1016/j.anireprosci.2020.106358
brgfx. (n.d.). Beagle dog cartoon on white background [Free vector illustration]. Magnific. https://www.magnific.com/free-vector/beagle-dog-cartoon-white-background_18921026.htm
Faro, T. A. S., & de Oliveira, E. H. C. (2023). Canine transmissible venereal tumor — from general to molecular characteristics: A review. Animal Genetics, 54(1), 82–89. https://doi.org/10.1111/age.13260
Ganguly, B., Das, U., & Das, A. K. (2016). Canine transmissible venereal tumour: A review. Veterinary and Comparative Oncology, 14(1), 1–12. https://doi.org/10.1111/vco.12060
GIS Geography. (n.d.). High resolution world map. GISGeography.com. Retrieved June 2025, from https://gisgeography.com/high-resolution-world-map/
Los Angeles County Department of Public Health, Veterinary Public Health. (2025). Transmissible venereal tumor (TVT) in dogs. LAC DPH. http://ph.lacounty.gov/vet/TVT/
Merck Veterinary Manual. (2024). Canine transmissible venereal tumor. Merck & Co. https://www.merckvetmanual.com/reproductive-system/canine-transmissible-venereal-tumor
Reis Filho, N. (2024). Therapeutics and management of persistent cases of canine transmissible venereal tumour: An update. Animal Reproduction Update, 4(2), 1–8. https://doi.org/10.48165/aru.2023.4.2.1
Schectman, S. J., Khanam, A., Walters, M. N. D., Kirwan, E., Sylvester, W. R., & Khan, F. A. (2022). A retrospective study of canine transmissible venereal tumour in Grenada, West Indies. Veterinary Medicine and Science, 8, 1008–1012. https://doi.org/10.1002/vms3.778
Souto, E. P. F., Rissi, D. R., Oliveira, A. M., Garcia, D. S., Mota, R. A., de Souza, A. P., Galiza, G. J. N., & Dantas, A. F. M. (2025). Transmissible venereal tumour with encephalic metastasis in dogs. Journal of Comparative Pathology, 216, 25–32. https://doi.org/10.1016/j.jcpa.2024.11.004
Strakova, A., & Murchison, E. P. (2014). The changing global distribution and prevalence of canine transmissible venereal tumour. BMC Veterinary Research, 10, 168. https://doi.org/10.1186/s12917-014-0168-9
This article is intended for general client education and does not constitute a clinical diagnosis or replace professional veterinary advice. If your pet is showing signs consistent with CTVT or any other illness, please contact The Andys Veterinary Clinic or your veterinarian promptly.
Comments